Value of Abciximab in Patients With AMI Undergoing Primary PCI After Clopidogrel Pretreatment (BRAVE 3)

PHASE4CompletedINTERVENTIONAL
Enrollment

800

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

February 29, 2008

Study Completion Date

March 31, 2008

Conditions
Myocardial Infarction
Interventions
DRUG

Abciximab

Abciximab bolus and infusion is given. Study medication includes 3 identical vials, each with 5 ml solution containing 10 mg abciximab. The bolus dose to be given should be rated at 0.125 ml/kg of patient's weight. After the bolus, a total dose of 0.045 ml/kg study substance (up to a maximal quantity of 3.6 ml) should be given over 12 hours.

OTHER

Placebo Heparin Sodium

Placebo bolus plus infusion is given. Study medication includes 3 identical vials, each with 5 ml solution containing 3000 U Heparin. The bolus dose to be given should be rated at 0.125 ml/kg of patient's weight. After the bolus, a total dose of 0.045 ml/kg study substance (up to a maximal quantity of 3.6 ml) should be given over 12 hours.

Trial Locations (5)

1090

Allgemeines Krankenhaus Wien, Vienna

80636

Deutsches Herzzentrum Muenchen, Munich

81675

First Medizinische Klinik, Klinikum rechts der Isar, Munich

82467

Klinikum Garmisch-Partenkirchen, Garmisch-Partenkirchen

83278

Klinikum Traunstein, Traunstein

All Listed Sponsors
collaborator

Technical University of Munich

OTHER

lead

Deutsches Herzzentrum Muenchen

OTHER

NCT00133250 - Value of Abciximab in Patients With AMI Undergoing Primary PCI After Clopidogrel Pretreatment (BRAVE 3) | Biotech Hunter | Biotech Hunter